OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
- OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
- OmniAb launched two new technologies during 2023 including OmniDeep™ and, during the fourth quarter, OmnidAb™.
- Fourth quarter 2023 and recent partner highlights include the following:
Immunovant reported positive initial results for batoclimab in Graves’ disease (GD). - OmniAb was added to the Nasdaq Biotechnology Index (NBI) in the fourth quarter.